Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Plasmacytoma 2Paraproteinemias 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Carcinoma, Non-Small-Cell Lung 2Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Recurrence 1Prostatic Neoplasms 1Patient Preference 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leiomyoma 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Injections, Subcutaneous × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡